Nothing Special   »   [go: up one dir, main page]

CR20200255A - Análogos de incretina y sus usos - Google Patents

Análogos de incretina y sus usos

Info

Publication number
CR20200255A
CR20200255A CR20200255A CR20200255A CR20200255A CR 20200255 A CR20200255 A CR 20200255A CR 20200255 A CR20200255 A CR 20200255A CR 20200255 A CR20200255 A CR 20200255A CR 20200255 A CR20200255 A CR 20200255A
Authority
CR
Costa Rica
Prior art keywords
incretin analogs
activity
receptors
incretin
analogs
Prior art date
Application number
CR20200255A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Lili Guo
Hongchang Qu
Tamer Coskun
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20200255A publication Critical patent/CR20200255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)

Abstract

Se proporcionan análogos de incretina que tienen actividad en cada uno de los receptores de GIP, GLP-1 y glucagón. Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan métodos para tratar enfermedades tales como diabetes mellitus, dislipidemia, hepatopatía grasa, síndrome metabólico, esteatohepatitis no alcohólica y obesidad.
CR20200255A 2017-12-21 2018-12-14 Análogos de incretina y sus usos CR20200255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21
PCT/US2018/065663 WO2019125938A1 (en) 2017-12-21 2018-12-14 Incretin analogs and uses thereof

Publications (1)

Publication Number Publication Date
CR20200255A true CR20200255A (es) 2020-07-12

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200255A CR20200255A (es) 2017-12-21 2018-12-14 Análogos de incretina y sus usos

Country Status (25)

Country Link
US (2) US11542313B2 (es)
EP (1) EP3727426A1 (es)
JP (2) JP6961838B2 (es)
KR (2) KR102444783B1 (es)
CN (1) CN111491658B (es)
AR (1) AR113486A1 (es)
AU (1) AU2018388962B2 (es)
BR (1) BR112020010244A2 (es)
CA (1) CA3084005C (es)
CL (1) CL2020001635A1 (es)
CO (1) CO2020006255A2 (es)
CR (1) CR20200255A (es)
DO (1) DOP2020000123A (es)
EA (1) EA202091290A1 (es)
EC (1) ECSP20032650A (es)
IL (1) IL275468A (es)
JO (1) JOP20200137A1 (es)
MA (1) MA51288A (es)
MX (2) MX2020006548A (es)
NZ (1) NZ765277A (es)
PE (1) PE20210162A1 (es)
PH (1) PH12020551025A1 (es)
SG (1) SG11202005606VA (es)
TW (3) TWI744579B (es)
WO (1) WO2019125938A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
KR20210091230A (ko) * 2018-11-12 2021-07-21 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 글루카곤 유도 펩티드 및 이의 용도
MX2022002115A (es) 2019-08-19 2022-03-17 Lilly Co Eli Metodos para preparar analogos de incretina.
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR121650A1 (es) * 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
WO2022090447A1 (en) 2020-10-30 2022-05-05 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
CN114685642B (zh) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
TWI837615B (zh) 2021-03-23 2024-04-01 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
AU2022280225A1 (en) 2021-05-26 2024-01-04 The United Bio-Technology (Hengqin) Co., Ltd. Multi-agonist and use thereof
WO2022268029A1 (zh) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Glp-1、gcg和gip受体的三重激动剂
CN117915939A (zh) 2021-06-23 2024-04-19 伊莱利利公司 肠降血糖素类似物用于血糖控制和体重管理
EP4434536A1 (en) * 2021-11-19 2024-09-25 Medshine Discovery Inc. Stapled peptide and use thereof
TWI828434B (zh) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 釘合肽及其應用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114957387B (zh) * 2022-05-18 2023-06-20 华南理工大学 一种具有降血糖作用的巴旦木多肽及其制备方法与应用
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
CN117417411A (zh) * 2022-09-28 2024-01-19 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2024213022A1 (zh) * 2023-04-11 2024-10-17 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
CN117024528B (zh) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 一种Retatrutide的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010013453A (es) * 2008-06-17 2011-01-21 Univ Indiana Res & Tech Corp Agonistas mezclados basados en gip para el tratamiento de desordenes metabolicos y obesidad.
KR20110137819A (ko) 2009-03-27 2011-12-23 글락소 그룹 리미티드 약물 융합체 및 컨쥬게이트
BR112012018104A2 (pt) * 2010-01-20 2017-10-17 Zeland Pharma As tratamento de doenças cardíacas
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2707713A2 (en) * 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
EA035688B1 (ru) * 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
TWI670281B (zh) * 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI669309B (zh) * 2015-06-22 2019-08-21 美商美國禮來大藥廠 升糖素及ｇｌｐ－１共激動劑化合物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
SG11201805573RA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
EP3217027A1 (de) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Breites einlageelement zum einfassen einer ankerstange
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos

Also Published As

Publication number Publication date
TWI744579B (zh) 2021-11-01
KR102622642B1 (ko) 2024-01-10
ECSP20032650A (es) 2020-07-31
DOP2020000123A (es) 2020-08-31
US11542313B2 (en) 2023-01-03
TW201938188A (zh) 2019-10-01
NZ765277A (en) 2024-08-30
PH12020551025A1 (en) 2021-09-06
IL275468A (en) 2020-08-31
MX2020006548A (es) 2020-09-14
US20230203121A1 (en) 2023-06-29
EA202091290A1 (ru) 2020-09-10
JP6961838B2 (ja) 2021-11-05
JP2021506955A (ja) 2021-02-22
MA51288A (fr) 2021-03-31
MX2024010201A (es) 2024-08-26
EP3727426A1 (en) 2020-10-28
CL2020001635A1 (es) 2020-10-16
CN111491658B (zh) 2024-04-26
JP2022033724A (ja) 2022-03-02
AU2018388962B2 (en) 2020-11-19
KR102444783B1 (ko) 2022-09-19
PE20210162A1 (es) 2021-01-26
TWI809515B (zh) 2023-07-21
BR112020010244A2 (pt) 2020-10-13
AR113486A1 (es) 2020-05-06
US20200331980A1 (en) 2020-10-22
KR20220133304A (ko) 2022-10-04
CA3084005C (en) 2024-01-02
WO2019125938A1 (en) 2019-06-27
CO2020006255A2 (es) 2020-05-29
KR20200088419A (ko) 2020-07-22
TW202202518A (zh) 2022-01-16
AU2018388962A1 (en) 2020-06-04
CA3084005A1 (en) 2019-06-27
TW202415675A (zh) 2024-04-16
CN111491658A (zh) 2020-08-04
JOP20200137A1 (ar) 2022-10-30
SG11202005606VA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
MX2024010201A (es) Analogos de incretina y sus usos.
PH12020551024A1 (en) Incretin analogs and uses thereof
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
TN2017000148A1 (en) Co-agonists of the glucagon and glp-1 receptors
MX368435B (es) Analogos del glucagon.
PH12016500675B1 (en) Acylated glucagon analogues
PH12015500531A1 (en) Glucagon analogues
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
CR11849A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad
MX2017012864A (es) Analogo acilado del glucagon.
MX2022007666A (es) Analogos de incretina y sus usos.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.